Medication related osteonecrosis of the jaw (MRONJ): A retrospective survey of a series of patients treated according to the AAOMS guidelines

ObjectivesThis study reviews the treatment outcome of patients (1) who referred to our hospital for preventive care using both bisphosphonate and related drugs (Non-MRONJ patient) and (2) who already have ongoing MRONJ symptoms (MRONJ patient) based on the AAOMS's guidelines.Patients and methodsA total of 106 patients referred to our hospital during 2012–2014 were retrospectively reviewed for their characteristics and the treatment outcomes. A multiple logistic regression analysis was performed on the MRONJ patient to assess whether the clinical variables could have correlation with the progress.ResultsThere were 18 males and 88 females in this study. Osteoporosis was higher as the primary disease among other diseases in both groups. More Non-MRONJ patients tend to take Risedronate over the other drugs and more Zoledronate have administrated in MRONJ patients than the others. The affected site for MRONJ was more frequently localized in the mandible and the treatment success rate of MRONJ patient was 56.5%. In Non-MRONJ patients, dento-alveolar surgery was performed with 98.8% good progress. C-reactive protein, total cholesterol from the blood examination data and patient's intraoral condition showed statistical significance by the prognostic study of the treatment outcome in MRONJ patient.ConclusionsThe treatment progress of Non-MRONJ patients seemed consistent with the previous reports in terms of the success rate. MRONJ patients showed somewhat lower success rate than the previous reports and some clinical variables such as total cholesterol seems to possibly influence the MRONJ treatment outcomes. An extensive survey will be required for further evidence.